v3.26.3
Segment Information
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Information

20. Segment Information

 

There have been no material changes in the Company’s segments since December 31, 2025, except as disclosed below. Refer to Note 17 – Segment Information in the Company’s 2025 Annual Report on Form 10-K for additional information and definitions of certain terms used in this Note.

 

Financial information by segment for the three months ended June 30, 2026 and 2025 is as follows:

 

   Cell Therapy   BioBanking   Degenerative Disease   Other   Total 
   Three Months Ended June 30, 2026 
   Cell Therapy   BioBanking   Degenerative Disease   Other   Total 
Net revenues  $1,339   $652   $3,441   $-   $5,432 
Cost of revenues   -    227    2,120    -    2,347 
Direct expenses   1,808    164    224    4,772    6,968 
Segment contribution  $(469)  $261   $1,097   $(4,772)  $(3,883)
Indirect expenses (a)                       354 
Loss from operations                      $(4,237)
Other income, net                      $4,943 
Income before income taxes                      $706 

 

  

Cell

Therapy

   BioBanking  

Degenerative

Disease

   Other   Total 
   Three Months Ended June 30, 2025 
  

Cell

Therapy

   BioBanking  

Degenerative

Disease

   Other   Total 
Net revenues  $759   $1,275   $3,702   $—   $5,736 
Cost of revenues (excluding amortization of acquired intangible assets)   —    220    5,022    —    5,242 
Direct expenses   2,927    387    1,854    10,818    15,986 
Segment contribution  $(2,168)  $668   $(3,174)  $(10,818)  $(15,492)
Indirect expenses (a)                  372    372 
Loss from operations                      $(15,864)
 Other expense, net                      $(8,660)
 Income before income taxes                      $(24,524)

 

(a) Comprised of amortization of intangible assets.

 

 

Financial information by segment for the six months ended June 30, 2026 and 2025 is as follows:

 

   Cell Therapy   BioBanking   Degenerative Disease   Other   Total 
   Six Months Ended June 30, 2026 
   Cell Therapy   BioBanking   Degenerative Disease   Other   Total 
Net revenues  $1,832   $1,902   $5,544   $-   $9,278 
Cost of revenues   -    449    3,350    -    3,799 
Direct expenses   4,275    407    1,812    12,633    19,127 
Segment contribution  $(2,443)  $1,046   $382   $(12,633)  $(13,648)
Indirect expenses (a)                  722    722 
Loss from operations                      $(14,370)
Other income, net                      $15,950 
Income before income taxes                      $1,580 

 

  

Cell

Therapy

   BioBanking  

Degenerative

Disease

   Other   Total 
   Six Months Ended June 30, 2025 
  

Cell

Therapy

   BioBanking  

Degenerative

Disease

   Other   Total 
Net revenues  $1,023   $2,683   $13,456   $—   $17,162 
Cost of revenues (excluding amortization of acquired intangible assets)   —    429    8,367    —    8,796 
Direct expenses   6,184    756    6,601    20,435    33,976 
Segment contribution  $(5,161)  $1,498   $(1,512)  $(20,435)  $(25,610)
Indirect expenses (a)                  740    740 
Loss from operations                      $(26,350)
Other expense, net                      $(17,928)
Net loss before income taxes                 -  $(44,278)

 

(a)Comprised of amortization of intangible assets.